Ivosidenib
FDA-approved product (tablet, oral), marketed as Tibsovo.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Acute myeloid leukemia
- Cholangiocarcinoma
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Isocitrate dehydrogenase (idh) inhibitors
- FDA pharmacologic class
- Isocitrate Dehydrogenase 1 Inhibitor FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA58.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli50.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae34.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Ivosidenib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- PlecanatideExisting use: Constipation52.2% AI-predicted activityagainst K. pneumoniae15 registered studies
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma51.3% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome50.5% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Terlipressin AcetateExisting use: Hepatorenal syndrome, Kidney failure, Renal insufficiency49.5% AI-predicted activityagainst K. pneumoniae7 registered studies
- LetermovirExisting use: Cytomegalovirus infection, Infection, Viral disease49.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Codeine SulfateExisting use: Cough, Drug dependence, Migraine disorder and 2 more48.8% AI-predicted activityagainst K. pneumoniae23 registered studies
- Bromocriptine MesylateExisting use: Acromegaly, Adenoma, Hyperprolactinemia and 4 more48.5% AI-predicted activityagainst K. pneumoniae50+ registered studies
- PimecrolimusExisting use: Atopic eczema, Eczematoid dermatitis48.3% AI-predicted activityagainst K. pneumoniae50+ registered studies
- LypressinExisting use: Vasopressin and analogues48.2% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Degarelix AcetateExisting use: Prostate adenocarcinoma, Prostate cancer, Prostate carcinoma48.2% AI-predicted activityagainst K. pneumoniae50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more48.1% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Dolutegravir SodiumExisting use: HIV infection, HIV-1 infection47.9% AI-predicted activityagainst K. pneumoniae50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia
NCT04250051 · start 2020-12-21
Registered record
- Registry ID
- NCT04250051
- Conditions
- Recurrent Acute Myeloid Leukemia; Recurrent Myelodysplastic Syndrome; Recurrent Myeloproliferative Neoplasm; Refractory Acute Myeloid Leukemia; Refractory Myelodysplastic Syndrome; Newly Diagnosed Acute Myeloid Leukemia (AML); IDH1 Mutation Myeloid Neoplasms; Acute Myeloid Leukemia (AML)
- Interventions
- Cytarabine; Filgrastim; Fludarabine; Fludarabine Phosphate; Ivosidenib; Idarubicin
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Terminated
- Start
- 2020-12-21
- Completion
- 2022-12-20
- Enrolment
- 2
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRecurrent Acute Myeloid Leukemia; Recurrent Myelodysplastic Syndrome; Recurrent Myeloproliferative Neoplasm; Refractory Acute Myeloid Leukemia +4 moreInterventionCytarabine; Filgrastim; Fludarabine; Fludarabine Phosphate +2 morePhasePhase 1Registry statusTerminatedStudy of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
NCT04603001 · start 2020-11-19
Registered record
- Registry ID
- NCT04603001
- Conditions
- Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS); Chronic Myelomonocytic Leukemia (CMML); Myeloproliferative Neoplasms (MPNs)
- Interventions
- LY3410738; Venetoclax; Azacitidine
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Active not recruiting
- Start
- 2020-11-19
- Completion
- 2027-05
- Enrolment
- 260
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS); Chronic Myelomonocytic Leukemia (CMML); Myeloproliferative Neoplasms (MPNs)InterventionLY3410738; Venetoclax; AzacitidinePhasePhase 1Registry statusActive not recruitingIvosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
NCT04195555 · start 2020-07-20
Registered record
- Registry ID
- NCT04195555
- Conditions
- Recurrent Ependymoma; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Glioma; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Rhabdoid Tumor; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Recurrent WHO Grade 2 Glioma; Refractory Ependymoma; Refractory Ewing Sarcoma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Glioma; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma; Refractory WHO Grade 2 Glioma
- Interventions
- Ivosidenib
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Active not recruiting
- Start
- 2020-07-20
- Completion
- 2027-05-09
- Enrolment
- 3
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRecurrent Ependymoma; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis +28 moreInterventionIvosidenibPhasePhase 2Registry statusActive not recruitingA Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS
NCT04044209 · start 2020-02-12
Registered record
- Registry ID
- NCT04044209
- Conditions
- Myelodysplastic Syndromes; Acute Myeloid Leukemia
- Interventions
- AG-120; Nivolumab
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Withdrawn
- Start
- 2020-02-12
- Completion
- 2023-09
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMyelodysplastic Syndromes; Acute Myeloid LeukemiaInterventionAG-120; NivolumabPhasePhase 2Registry statusWithdrawnIDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome
NCT03503409 · start 2019-05-14
Registered record
- Registry ID
- NCT03503409
- Conditions
- Myelodysplastic Syndromes; Acute Myeloid Leukemia
- Interventions
- AG-120
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Active not recruiting
- Start
- 2019-05-14
- Completion
- 2027-04-02
- Enrolment
- 68
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMyelodysplastic Syndromes; Acute Myeloid LeukemiaInterventionAG-120PhasePhase 2Registry statusActive not recruitingA Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy
NCT03839771 · start 2019-03-01
Registered record
- Registry ID
- NCT03839771
- Conditions
- Acute Myeloid Leukemia; Myelodysplastic Syndrome With Excess Blasts-2
- Interventions
- AG-120; Placebo for AG-120; AG-221; Placebo for AG-221
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Active not recruiting
- Start
- 2019-03-01
- Completion
- 2034-09-19
- Enrolment
- 968
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Myeloid Leukemia; Myelodysplastic Syndrome With Excess Blasts-2InterventionAG-120; Placebo for AG-120; AG-221; Placebo for AG-221PhasePhase 3Registry statusActive not recruitingFrailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
NCT03680677 · start 2018-09-21
Registered record
- Registry ID
- NCT03680677
- Conditions
- Leukemia, Acute; MDS
- Interventions
- Bone Marrow or Peripheral Blood Graft (BMT); Cancer-directed Therapy or Best Supportive Care; Frailty Assessment
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Recruiting
- Start
- 2018-09-21
- Completion
- 2027-11
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLeukemia, Acute; MDSInterventionBone Marrow or Peripheral Blood Graft (BMT); Cancer-directed Therapy or Best Supportive Care; Frailty AssessmentPhaseNot recordedRegistry statusRecruitingA Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
NCT03498521 · start 2018-07-10
Registered record
- Registry ID
- NCT03498521
- Conditions
- Cancer of Unknown Primary Site
- Interventions
- Alectinib; Vismodegib; Ipatasertib; Olaparib; Erlotinib; Bevacizumab; Vemurafenib; Cobimetinib; Trastuzumab Subcutaneous (SC); Pertuzumab; Atezolizumab; Carboplatin; Paclitaxel; Cisplatin; Gemcitabine; Entrectinib; Ivosidenib; Pemigatinib
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2018-07-10
- Completion
- 2024-11-07
- Enrolment
- 529
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCancer of Unknown Primary SiteInterventionAlectinib; Vismodegib; Ipatasertib; Olaparib +14 morePhasePhase 2Registry statusCompletedIvosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
NCT03471260 · start 2018-03-19
Registered record
- Registry ID
- NCT03471260
- Conditions
- Acute Myeloid Leukemia; Hematopoietic and Lymphoid System Neoplasm; Myelodysplastic Syndrome; Myeloproliferative Neoplasm; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
- Interventions
- Azacitidine; Ivosidenib; Venetoclax
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Recruiting
- Start
- 2018-03-19
- Completion
- 2027-09-30
- Enrolment
- 96
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Myeloid Leukemia; Hematopoietic and Lymphoid System Neoplasm; Myelodysplastic Syndrome; Myeloproliferative Neoplasm +2 moreInterventionAzacitidine; Ivosidenib; VenetoclaxPhasePhase 1 / Phase 2Registry statusRecruitingA Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function
NCT03282513 · start 2017-09-26
Registered record
- Registry ID
- NCT03282513
- Conditions
- Hepatic Impairment
- Interventions
- AG-120 (Ivosidenib)
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2017-09-26
- Completion
- 2018-03-31
- Enrolment
- 33
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHepatic ImpairmentInterventionAG-120 (Ivosidenib)PhasePhase 1Registry statusCompletedTargeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
NCT03155620 · start 2017-07-31
Registered record
- Registry ID
- NCT03155620
- Conditions
- Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Histiocytic Sarcoma; Juvenile Xanthogranuloma; Langerhans Cell Histiocytosis; Malignant Glioma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Ependymoma; Recurrent Ewing Sarcoma; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Primary Central Nervous System Neoplasm; Recurrent Rhabdoid Tumor; Recurrent Soft Tissue Sarcoma; Refractory Ewing Sarcoma; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphom
- Interventions
- Biopsy Procedure; Biospecimen Collection; Bone Marrow Aspiration and Biopsy; Bone Scan; Computed Tomography; Ensartinib; Erdafitinib; Ivosidenib; Laboratory Biomarker Analysis; Larotrectinib Sulfate; Magnetic Resonance Imaging; Mutation Carrier Screening; Olaparib; Palbociclib; Pharmacological Study; Positron Emission Tomography; Radionuclide Imaging; Samotolisib; Selpercatinib; Selumetinib Sulfate; Tazemetostat; Tipifarnib; Ulixertinib; Vemurafenib; X-Ray Imaging
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Active not recruiting
- Start
- 2017-07-31
- Completion
- 2027-01-06
- Enrolment
- 1,377
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdvanced Malignant Solid Neoplasm; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Histiocytic Sarcoma +28 moreInterventionBiopsy Procedure; Biospecimen Collection; Bone Marrow Aspiration and Biopsy; Bone Scan +21 morePhasePhase 2Registry statusActive not recruitingStudy of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
NCT03173248 · start 2017-06-26
Registered record
- Registry ID
- NCT03173248
- Conditions
- Newly Diagnosed Acute Myeloid Leukemia (AML); Untreated AML; AML Arising From Myelodysplastic Syndrome (MDS); Leukemia, Myeloid, Acute
- Interventions
- AG-120; Placebo; Azacitidine
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Active not recruiting
- Start
- 2017-06-26
- Completion
- 2026-06-30
- Enrolment
- 146
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNewly Diagnosed Acute Myeloid Leukemia (AML); Untreated AML; AML Arising From Myelodysplastic Syndrome (MDS); Leukemia, Myeloid, AcuteInterventionAG-120; Placebo; AzacitidinePhasePhase 3Registry statusActive not recruitingJapanese Bridging Study of Ivosidenib (AG-120) in Healthy Subjects
NCT03071770 · start 2017-03-31
Registered record
- Registry ID
- NCT03071770
- Conditions
- Healthy
- Interventions
- ivosidenib (AG-120)
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2017-03-31
- Completion
- 2017-09-06
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionivosidenib (AG-120)PhasePhase 1Registry statusCompletedStudy of Biomarker-Based Treatment of Acute Myeloid Leukemia
NCT03013998 · start 2016-11
Registered record
- Registry ID
- NCT03013998
- Conditions
- Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
- Interventions
- Samalizumab (BAML-16-001-S1); BI 836858 (BAML-16-001-S2); Laboratory Biomarker Analysis; Daunorubicin (BAML-16-001-S1); Cytarabine (BAML-16-001-S1); Azacitidine (BAML-16-001-S2); AG-221 (BAML-16-001-S3); Azacitidine (BAML-16-001-S3); Entospletinib (BAML-16-001-S4); Azacitidine (BAML-16-001-S4); Entospletinib (BAML-16-001-S5); Decitabine (BAML-16-001-S5); Entospletinib (BAML-16-001-S6); Daunorubicin (BAML-16-001-S6); Cytarabine (BAML-16-001-S6); Pevonedistat (BAML-16-001-S9); Azacitidine (BAML-16-001-S9); AG-120 (BAML-16-001-S16); Azacitidine (BAML-16-001-S16); Gilteritinib (BAML-16-001-S8 Group 1); Decitabine (BAML-16-001-S8 Group 1); AZD5153 (BAML-16-001-S10); Venetoclax (BAML-16-001-S10); TP-0903 (BAML-16-001-S14); Decitabine (BAML-16-001-S14); Decitabine (BAML-16-001-S8 Group 2); Venetoclax (BAML-16-001-S8 Group 2); AZD5991 (BAML-16-001-S18); Azacitidine (BAML-16-001-S18); SNDX-5613 (BAML-16-001-S17); Azacitidine (BAML-16-001-S17); Venetoclax (BAML-16-001-S17); Gilteritinib (BAML-16
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Recruiting
- Start
- 2016-11
- Completion
- 2032-12
- Enrolment
- 3,000
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPreviously Untreated Relapsed Refractory Acute Myeloid LeukemiaInterventionSamalizumab (BAML-16-001-S1); BI 836858 (BAML-16-001-S2); Laboratory Biomarker Analysis; Daunorubicin (BAML-16-001-S1) +29 morePhasePhase 2 / Phase 3Registry statusRecruitingStudy of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
NCT02665065 · start 2016-06
Registered record
- Registry ID
- NCT02665065
- Conditions
- Acute Myeloid Leukemia; Leukemia, Acute Myeloid; Myeloid Leukemia, Acute; Leukemia, Myeloid, Acute; Acute Myelogenous Leukemia; Leukemia, Acute Myelogenous; Myelogenous Leukemia, Acute; AML; Bone Marrow Transplant
- Interventions
- Iomab-B; Conventional Care; HCT
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Active not recruiting
- Start
- 2016-06
- Completion
- 2026-12
- Enrolment
- 153
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Myeloid Leukemia; Leukemia, Acute Myeloid; Myeloid Leukemia, Acute; Leukemia, Myeloid, Acute +5 moreInterventionIomab-B; Conventional Care; HCTPhasePhase 3Registry statusActive not recruiting